Volume : 08, Issue : 10, October – 2021
Title:
09.DEVELOPMENT AND CHARACTERIZATION OF TRANSDERMAL PATCHES OF FEBUXOSTAT FOR TRANSDERMAL DELIVERY
Authors :
Deepti Yadav*, B.K Dubey, Mansi Gupta, Deepak Basedia.
Abstract :
The aim of this work is to formulate and evaluate transdermal patches containing Febuxostat as active pharmaceutical ingredient. The objective of the present investigation was to evaluate the transdermal films of Febuxostat to its applicability to reduce the dose of the drug. Febuxostat is an orally available non-purine xanathine oxidase (XO) inhibitor that has been indicated in treatment of patients diagnosed with gouty arthritis suffering from hyperuricemia and is used in the chronic management of the disease. The capability to be able to deliver hydrophilic drugs through a transdermal route may furnish a better solution to the problems associated with other methods for delivery of hydrophilic drugs. Due to their low absorption by the GI tract, hydrophilic drugs need to be administered orally in very large doses. This increases the cost of the drug and may carry harmful side effects. Increased efficacy of hydrophilic drugs in TDDS appeals to drug makers, physicians, and patients alike. The development of an effective TDDS, particularly for hydrophilic drugs, will increase the availability of drugs to patients and bring new hydrophilic drugs to the markets which were previous not viable due to their poor bioavailability with oral dosing. The patches were prepared with the help of a various polymers (Ethyl cellulose, Sodium alginate, and Polyethylene glycol 400). The patches FTDP3 were more transparent as compared to the patches. The evaluation parameters of transdermal patches were evaluated like (Weight variation, Thickness, Folding endurance, Moisture content, Drug content and In-Vitro Permeation study etc).
Keywords: Febuxostat, Transdermal Drug Delivery System, Carbopol 934, Transdermal Patches, Gout.
Cite This Article:
Please cite this article in press Deepti Yadav et al, Development And Characterization of Transdermal Patches of Febuxostat for Transdermal Delivery., Indo Am. J. P. Sci, 2021; 08(10).
Number of Downloads : 10
References:
1. Nautiyal U, Singh D. Formulation and characterization of transdermal patches of Losartan. Indian J Pharm Biol Res. 2013; 1(1): 44-54.
2. Jalwal P, Jangra A, Dahiya L, Sangwan Y, Saroha R. A review on transdermal patches. The Pharma Res. 2010; 3: 139-149.
3. Pastore MN, Kalia YN, Hostmann M, Roberts MS. Transdermal patches: history, development and pharmacology. British J Pharmacol. 2015; 172: 2179-2022.
4. Seth NS, Mistry RB. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of eugenol. J Applied Pharm Sci. 2011; 1(3): 96-101.
5. Raza R, Mittal A, Kumar P, Alam S, Prakash S, Chauhan N. Approaches and evaluation of transdermal drug delivery system. Int J Drug Del Res. 2015; 7(1): 222-233.
6. Patole BS, Shinkar DM, Saudagar RB. Patches: Novel approach for development of topical drug delivery system. J Adv Pharm Edu Res. 2013; 3(4): 347-358.
7. Patel DM. Formulation and evaluation aspects of transdermal drug delivery system. Int J Pharm Sci Rev Res. 2011; 6(2): 83-90.
8. Appendix 13.1 Buffers, In: Indian Pharmacopoeia, 1996, The Indian Pharmacopoeia Commission, Ghaziabad.
9. Chaurasia G. A review of pharmaceutical preformulation studies in formulation and development of new drug molecules. Int J Pharm Sci Res. 2016; 7(6): 2313-2320.
10. Mita SR, Rahayu D, Kurnawansyah IS, Chaerunisaa AY, Purnama H. Development of patch ketoprofen using chitosan as polymer matrix. J Pharm Sci Res. 2018; 10(1): 8-15.
11. Yadav AY, Urade MN. Formulation and evaluation of chitosan based transdermal patches of lornoxicam for prolonged drug release and to study the effect of permeation enhancer. Indian J Pharm Edu Res. 2019; 53(1): 88-96.
12. Kanke PK, Pathan IB, Jadhav A, Usman MRM. Formulation and evaluation of febuxostat nanoemulsion for transdermal drug delivery. J Pharm BioSci. 2019; 7(1): 1-7.